跳转至内容
Merck
CN
  • Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains.

Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains.

PloS one (2014-10-28)
Vikash Pandey, Marc Sultan, Karl Kashofer, Meryem Ralser, Vyacheslav Amstislavskiy, Julia Starmann, Ingrid Osprian, Christina Grimm, Hendrik Hache, Marie-Laure Yaspo, Holger Sültmann, Michael Trauner, Helmut Denk, Kurt Zatloukal, Hans Lehrach, Christoph Wierling
摘要

Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging from mild steatosis characterized by an abnormal retention of lipids within liver cells to steatohepatitis (NASH) showing fat accumulation, inflammation, ballooning and degradation of hepatocytes, and fibrosis. Ultimately, steatohepatitis can result in liver cirrhosis and hepatocellular carcinoma. In this study we have analyzed three different mouse strains, A/J, C57BL/6J, and PWD/PhJ, that show different degrees of steatohepatitis when administered a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) containing diet. RNA-Seq gene expression analysis, protein analysis and metabolic profiling were applied to identify differentially expressed genes/proteins and perturbed metabolite levels of mouse liver samples upon DDC-treatment. Pathway analysis revealed alteration of arachidonic acid (AA) and S-adenosylmethionine (SAMe) metabolism upon other pathways. To understand metabolic changes of arachidonic acid metabolism in the light of disease expression profiles a kinetic model of this pathway was developed and optimized according to metabolite levels. Subsequently, the model was used to study in silico effects of potential drug targets for steatohepatitis. We identified AA/eicosanoid metabolism as highly perturbed in DDC-induced mice using a combination of an experimental and in silico approach. Our analysis of the AA/eicosanoid metabolic pathway suggests that 5-hydroxyeicosatetraenoic acid (5-HETE), 15-hydroxyeicosatetraenoic acid (15-HETE) and prostaglandin D2 (PGD2) are perturbed in DDC mice. We further demonstrate that a dynamic model can be used for qualitative prediction of metabolic changes based on transcriptomics data in a disease-related context. Furthermore, SAMe metabolism was identified as being perturbed due to DDC treatment. Several genes as well as some metabolites of this module show differences between A/J and C57BL/6J on the one hand and PWD/PhJ on the other.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
L -还原型谷胱甘肽, suitable for cell culture, BioReagent, ≥98.0%, powder
Sigma-Aldrich
L -还原型谷胱甘肽, ≥98.0%
Sigma-Aldrich
精胺, ≥97%
Sigma-Aldrich
β-丙氨酸, 99%
Supelco
谷胱甘肽, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
DL-甲硫氨酸, ≥99%
Sigma-Aldrich
精胺, suitable for cell culture, BioReagent
Sigma-Aldrich
L -还原型谷胱甘肽, BioXtra, ≥98.0%
Sigma-Aldrich
嘌呤, 98%
Sigma-Aldrich
精胺, ≥99.0% (GC)
Sigma-Aldrich
DL-甲硫氨酸, 99%, FCC, FG
Sigma-Aldrich
β-丙氨酸, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
二乙基-1,4-二氢-2,4,6-三甲基-3,5-吡啶二羧酸酯, 99%
组氨酸, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
β-丙氨酸, BioXtra, ≥99.0% (NT)
谷胱甘肽, European Pharmacopoeia (EP) Reference Standard
Supelco
β-丙氨酸, Pharmaceutical Secondary Standard; Certified Reference Material
蛋氨酸, European Pharmacopoeia (EP) Reference Standard
Supelco
精胺, analytical standard
Sigma-Aldrich
DL-Histidine, ≥99% (TLC)
Supelco
β-丙氨酸, analytical standard
Sigma-Aldrich
β-丙氨酸, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
DL-甲硫氨酸, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥99%
Sigma-Aldrich
DL-甲硫氨酸, ≥99.0% (NT)
DL-甲硫氨酸, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L -还原型谷胱甘肽, Vetec, reagent grade, ≥98%